This brand name is authorized in Austria, Estonia, Croatia, Ireland, Italy, Lithuania, United Kingdom
The drug EBGLYSS contains one active pharmaceutical ingredient (API):
|
1
Lebrikizumab
UNII U9JLP7V031 - LEBRIKIZUMAB
|
|
Lebrikizumab is an immunoglobulin (IgG4) monoclonal antibody that binds with high affinity to interleukin (IL)-13 and selectively inhibits IL-13 signalling through the IL-4 receptor alpha (IL-4Rα)/ IL-13 receptor alpha 1 (IL-13Rα1) heterodimer, thereby inhibiting the downstream effects of IL-13. Inhibition of IL-13 signalling is expected to be of benefit in diseases in which IL-13 is a key contributor to the disease pathogenesis. Lebrikizumab does not prevent the binding of IL-13 to the IL-13 receptor alpha 2 (IL-13Rα2 or decoy receptor), which allows the internalisation of IL-13 into the cell. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| EBGLYSS Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: EE | Ravimiamet | Identifier(s): 3055980, 3055991, 3056004, 3056015, 3056026, 3056037, 3056048, 3056059, 3056060, 3056071, 3056082, 3056093 |
| Country: IT | Agenzia del Farmaco | Identifier(s): 050964016, 050964028, 050964030, 050964042, 050964079, 050964081, 050964093, 050964105, 050964117, 050964129 |
| Country: LT | Valstybinė vaistų kontrolės tarnyba | Identifier(s): 1098146, 1098147, 1098148, 1098149, 1098150, 1098151, 1098152, 1098153, 1098154, 1098155, 1098156, 1098157 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
